
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-41933

Haoxi Health Technology Limited

(Translation of registrant's name into English)

Room 801, Tower C, Floor 8, Building 103

Huizhongli, Chaoyang District

Beijing, China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Change in Registrant's Certifying Accountant

On April 2, 2026, of the audit committee (the "**Committee**") of the board of directors (the "**Board**") of Haoxi Health Technology Limited's (the "**Company**"), has resolved to dismiss the engagement of Wei, Wei & Co., LLP (the "**Former Auditor**") as the Company's independent registered public accounting firm, effective on April 3, 2026, and to appoint HCL, PLLC (the "**New Auditor**") to serve as its independent registered public accounting firm, effective on April 3, 2026.

During the two most recent fiscal years ended June 30, 2025 and 2024, and through the subsequent interim period preceding the release, the Former Auditor has neither provided any adverse opinion or qualifications on the Company's financial statements nor had a disagreement with the Company since their engagement on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements that, if not resolved to the Former Auditor's satisfaction, would have caused the Former Auditor to make reference to the subject matter thereof in its reports for such fiscal years and interim period.

During the two most recent fiscal years ended June 30, 2025 and 2024, and through the subsequent interim period preceding the release, there was no "reportable event" within the meaning of Item 16F(a)(1)(v) of Form 20-F.

The Company has provided the Former Auditor with a copy of this report prior to its filing with the U.S. Securities and Exchange Commission (the "**SEC**"). The Former Auditor has provided a letter to us and addressed to the SEC, which is attached hereto as Exhibit 16.1 and is hereby incorporated herein by reference.

During the two most recent fiscal years ended June 30, 2025 and 2024, and any subsequent interim periods prior to the engagement of the New Auditor, neither the Company, nor someone on behalf of the Company, has consulted New Auditor regarding (i) the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements; (ii) the type of audit opinion that might be rendered on the Company's financial statements by the New Auditor in either case where written or oral advice provided by the New Auditor would be an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issues; or (iii) any matter that was either the subject of a disagreement (as defined in paragraph (a)(1)(iv) of Item 304 of Regulation S-K and the related instructions thereto) or a reportable event (as described in paragraph (a)(1)(v) of Item 304 of Regulation S-K).

EXHIBIT INDEX

Number	Description of Exhibit
16.1	Letter from Wei, Wei & Co., LLP to the U.S. Securities and Exchange Commission

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Haoxi Health Technology Limited

By: /s/ Zhen Fan

Zhen Fan

Chief Executive Officer

Date: April 6, 2026



• **MAIN OFFICE**
133-10 39TH AVENUE
FLUSHING, NY 11354
TEL. (718) 445-6308
FAX. (718) 445-6760

• **CALIFORNIA OFFICE**
440 E HUNTINGTON DR.
STE 300
ARCADIA, CA 91006
TEL. (626) 282-1630
FAX. (626) 282-9726

• **BEIJING OFFICE**
11/F NORTH TOWER
BEIJING KERRY CENTRE
1 GUANGHUA ROAD
CHAOYANG DISTRICT
BEIJING, 100020, PRC
TEL. (86 10) 65997923
FAX. (86 10) 65999100

U.S. Securities and Exchange Commission
Office of the Chief Accountant
100 F Street Northeast
Washington, DC 20549

RE: Haoxi Health Technology Ltd.
CIK: 0001954594

We have been furnished a copy of the statements being made by Haoxi Health Technology Ltd. (the "Company") in its Form 6-K dated April 6, 2026 and captioned "Changes of Auditor". We acknowledge that Wei, Wei & Co., LLP had issued audit reports on the consolidated financial statements of the Company for the years ended June 30, 2025 and 2024.

During the period from August 3, 2022, the date of our appointment as the Company's independent registered public accounting firm, through April 6, 2026, the date of our dismissal, there were no disagreements between us and the Company regarding accounting principles that we need to make reference to.

We agree with all statements pertaining to us in such Form 6-K. We have no basis to agree or disagree with any other statements of the Registrant contained in Exhibit 16.1.

Sincerely,

Wei, Wei & Co., LLP